1	Severe haemolysis during primaquine radical cure of <i>Plasmodium</i>
2	vivax malaria: two systematic reviews and individual patient data
3	descriptive analyses
4	Daniel Yilma ^{1,2,3} *, Emily S Groves ⁴ , Jose Diego Brito-Sousa ⁵⁻⁶ , Wuelton M Monteiro ⁵⁻⁶ , Cindy Chu ⁷ ,
5	Kamala Thriemer ⁴ , Robert J Commons ^{4,8} , Marcus V G Lacerda ^{5,9} , Ric N Price ^{4,10,11} , Nicholas M
6	Douglas ^{4,12,13} *
7	
8 9	1. Jimma University Clinical Trial Unit, Department of Internal Medicine, Jimma University, Jimma, Ethiopia
10	2. WorldWide Antimalarial Resistance Network, Oxford, UK
11 12	3. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
13 14	4. Division of Global and Tropical Health, Menzies School of Health Research and Charles Darwin University, Darwin, PO Box 41096, Casuarina NT 0811, Australia
15 16	5. Instituto de Pesquisa Clínica Carlos Borborema, Fundacão de Medicina Tropical Dr Heitor Vieira Dourado, Manaus, Brazil
17	6. Escola Superior de Ciências da Saude, Universidade do Estado do Amazonas, Manaus, Brazil
18 19	7. Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medical Research Unit, Faculty of Tropical Medicine, Mahidol University, MaeSot, Tak, Thailand
20	8. General and Subspecialty Medicine, Grampians Health, Ballarat, Victoria, Australia
21	9. Instituto Leônidas & Maria Deane, Fundação Oswaldo Cruz, Manaus, Brazil
22 23	10. Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, University of Oxford, OX37LJ, UK
24 25	11. Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
26	12. Department of Medicine, University of Otago, Christchurch, New Zealand
27	13. Department of Infectious Diseases, Christchurch Hospital, Christchurch, New Zealand

- 28 * Corresponding authors
- 29 Email: <u>nick.douglas@otago.ac.nz</u>
- 30 Email: <u>danielyilmab@gmail.com</u>
- 31
- 32
- 33

34 Abstract:

35 Background

36 Primaquine (PQ) kills *Plasmodium vivax* hypnozoites but can cause haemolysis in patients with glucose-6-

37 phosphate dehydrogenase (G6PD) deficiency.

38 Methods

We did two systematic reviews: the first used data from clinical trials to determine the spectrum of definitions and frequency of haematological serious adverse events (SAE) related to PQ treatment of vivax malaria. The second used data from prospective studies and case reports to describe the clinical presentation, management and outcome of 'severe' PQ-associated haemolysis necessitating hospitalisation.

43 Findings

44 In the first review, SAEs were reported in 70 of 249 clinical trials. There were 34 haematological SAEs 45 amongst 9,824 patients with vivax malaria treated with PQ, 9 of which necessitated hospitalisation or blood 46 transfusion. Criteria used to define SAEs were diverse. In the second review, 21 of 8,487 articles screened reported 163 patients hospitalised following PQ radical cure; 79.9% (123/154) of whom were prescribed 47 PQ at ≥ 0.5 mg/kg/day. Overall, 101 patients were categorised as having probable or possible 'severe' PQ-48 49 associated haemolysis, 96.8% of whom were G6PD deficient (<30% activity). The first symptoms of 50 haemolysis were mostly reported on day 2 or 3 (45.5%) and all patients were hospitalised within 7 days of 51 PQ commencement. 57.9% (77/133) of patients had blood transfusion. Seven (6.9%) patients with probable 52 or possible haemolysis died.

53 Interpretation

- 54 Even when G6PD testing is available, enhanced monitoring for haemolysis is warranted following PQ
- treatment. Clinical review within the first 5 days of treatment may facilitate early detection and management
- of haemolysis. More robust definitions of severe PQ-associated haemolysis are required.
- 57 Funding: WHO-TDR, Australian National Health and Medical Research (NHMRC), The Bill & Melinda
- 58 Gates Foundation.
- 59 Key words: Primaquine, malaria, *Plasmodium vivax*, haemolysis, glucose-6-phosphate dehydrogenase
- 60 deficiency; adverse event

62 Introduction

63 *Plasmodium vivax* forms dormant liver stages (hypnozoites) that can reactivate periodically, causing recurrent blood stage malaria infections known as relapses. Primaguine (PO) is an 8-aminoquinoline drug 64 that has been used for malaria treatment and prophylaxis since the 1950s. It is the only widely available 65 66 antimalarial that eliminates P. vivax hypnozoites and thus can prevent relapses. The World Health 67 Organization (WHO) recommends PQ for radical cure of P. vivax or P. ovale malaria in all malaria 68 transmission settings in children and adults except pregnant women, infants aged <6 months, women 69 breastfeeding infants <6 months and women breastfeeding older infants with unknown glucose-6-phosphate 70 dehydrogenase (G6PD) status.¹

PQ can cause severe drug-induced haemolysis, particularly in individuals predisposed to oxidant erythrocytic damage due to functional deficiency of the enzyme G6PD.²⁻⁴ G6PD deficiency is the commonest human enzymopathy globally and is particularly prevalent in malaria endemic regions.^{5,6} Patients with PQ-induced haemolysis can develop severe anaemia necessitating blood transfusion and haemoglobinuria, potentially leading to kidney damage.⁷ If severe, PQ-associated haemolysis can be fatal.⁸

The WHO recommends G6PD activity assessment prior to administration of PQ for radical cure,¹ but there is limited access to practicable assays in malaria endemic regions.⁹ PQ treatment is therefore often not implemented due to the risks of haemolysis with unguided use.¹⁰ Conversely patients with *P. vivax* malaria who are not treated with PQ radical cure can have major deleterious consequences from multiple relapses, including severe anaemia.^{11,12} Policymakers therefore need to weigh potential risks of PQ-associated haemolysis against the risks of recurrent malaria when deciding on treatment protocols. To do this, they need robust data on the incidence and outcomes of PQ-attributable severe haemolysis.

The diagnosis of haemolysis secondary to PQ is typically based on a fall in haemoglobin and/or clinical
manifestations suggestive of intravascular haemolysis. Definitions for 'severe' or clinically significant PQ-

associated haemolysis are not established. Attribution of haemolysis to PQ is difficult in the presence of
concomitant parasitaemia.

We did two complementary systematic reviews to inform and standardise PQ pharmacovigilance practices and to facilitate quantification of the risks and benefits of different radical cure strategies. The aim of the first review was to determine the spectrum of definitions and frequency of haemolytic serious adverse events (SAEs) in patients enrolled into prospective *P. vivax* antimalarial clinical efficacy trials. The second review used individual patient data from case reports and prospective studies to describe the clinical presentation, management and outcome of patients with severe PQ-associated haemolysis who required hospitalisation for clinical management.

94

95 Methods

96 Review 1 - Serious adverse events in clinical trials

The first systematic review used data from the WorldWide Antimalarial Resistance Network (WWARN) 97 "vivax surveyor".¹³ This repository contains details of all *P. vivax* antimalarial clinical efficacy studies done 98 99 between Jan 1960 and August 23, 2021 (previously registered at PROSPERO [CRD42016053228]). To be 100 eligible for inclusion in the current review, trials had to have been done since 1990 and include one or more 101 treatment arm(s) in which patients were treated with either partial or fully supervised PQ therapy for at least 102 5 days (Box 1 - appendix pp5). PQ administration had to commence within 7 days of starting blood 103 schizontocidal therapy. Data from non-PQ-containing arms in these studies were also extracted for 104 comparative purposes. Studies meeting the above criteria, but not reporting the presence or absence of adverse effects of treatment, were excluded. 105

Generic definitions of <u>serious adverse events</u> (SAEs) have been standardised¹⁴ and generally speaking
 encompass events that are life-threatening or require hospitalisation. In this review, the respective authors'

108 classification of events as SAEs was accepted but the clinical and laboratory criteria used by the authors to

109 classify the events as SAEs were outcomes of interest.

Data were extracted into Microsoft Excel[®] including the number of patients enrolled into each treatment 110 111 arm, patient demographics, clinical and laboratory features, the number of patients experiencing any authorreported SAE, the relationship of SAE to PO administration and the number of haematological SAEs. 112 'Severe' haematological adverse events (defined a priori as a haematological event requiring 113 114 hospitalisation, blood transfusion, renal replacement therapy or death) were assigned after data extraction 115 based on the clinical data available. Original investigators were approached for missing data and where 116 possible the clinical and laboratory data used by the original investigators to classify episodes as 117 haematological SAE were collected for individual patients. Laboratory methods used to screen for G6PD 118 deficiency (if performed) and individual G6PD activity measurements of patients experiencing a 119 haematological SAE were also collected.

120

121 Review 2 - Severe primaquine-associated haemolysis

In the second systematic review, all articles in any language reporting at least one case of severe PQassociated haemolysis were identified. To be eligible for inclusion, papers had to report data attributable to individual patients receiving PQ for *P. vivax* radical cure or terminal prophylaxis. The review was registered at PROSPERO [CRD42020196604]. The term **severe haemolysis** was used to define a clinical event requiring hospitalisation, blood transfusion, renal replacement therapy or death, which the original investigators attributed to haemolysis or anaemia. Children <6 months of age and pregnant or lactating women were excluded from the analysis as both are ineligible for PQ treatment.

We searched PubMed, Web of Science, Embase and the Cochrane Central Database for eligible reports published between 1 January 1940 and 20 May 2020, according to PRISMA guidelines (PRIMSA Checklist - appendix pp2-4). The search terms are presented in (box 2 appendix pp6). We also searched articles included in the WWARN *P. vivax* clinical trial database used in the first systematic review,¹³ as well as reference lists from identified articles and documents, conference abstracts and unpublished works from our network of collaborators. The review process was undertaken by six independent reviewers (DY, EG, KT, RJC, NMD, RNP), with discrepancies resolved by discussion.

Data from relevant reports were extracted into a standardised RedCap[®] database, including the source of data, patient demographics, PQ dose regimen, G6PD activity and all available clinical and laboratory features of the haemolytic event (see Supplementary Data File). Authors of eligible studies were contacted and asked to provide relevant additional information that was not reported in the publication. All data were de-identified. From the data available, the certainty of the diagnosis of PQ-associated severe haemolysis was categorised as "Probable", "Possible" or "Uncertain" using an *a priori* hierarchical evidence scale (see box 1).

143

144 Statistical analyses

Statistical analyses and graphing were conducted using STATA version 15.1 (StataCorp, College Station, USA). The dose of PQ was categorised according to the daily dose as low (<0.375 mg/kg/day), intermediate (0.375 - <0.75 mg/kg/day) or high ($\ge 0.75 \text{ mg/kg/day}$). Continuous variables are presented as median, range and interquartile range (IQR). Categorical variables are presented as number and proportion. Qualitative G6PD testing was assumed to detect deficiency in patients with less than 30% enzyme activity. The risks of SAEs reported in clinical trials were stratified *a priori* into three groups: patients with unknown G6PD

status, patients with G6PD activity >30%, and females with G6PD activity >30%.

152

153 Ethics

Original studies received ethical approval via the relevant approval authorities. Ethical approval for this
systematic review was obtained from the Human Research Ethics Committee of the Northern Territory
Department of Health and Menzies School of Health Research (HREC reference number: 2020-3935).

1	58
---	----

159

 Hb recorded: Fall in Hb to < 7g/dL and >25% fractional fall Fall in Hb ≥5g/dL (Fall in Hb 3-4.99 g/dL or >25% fall) AND (dark, brown or red urine or jaundice or shortness of breath or heart failure or blood transfusion or renal replacement therapy or death) Hb recorded after PQ: Hb <7g/dL AND (dark, brown or red urine or jaundice) AND (shortness of breath or heart failur or blood transfusion or renal replacement therapy or death) ble o recorded: (dark urine or jaundice) AND (blood transfusion or renal replacement therapy or death) Hb <7g/dL AND (dark, brown, or red urine or jaundice or shortness of breath or heart failure or blood transfusion or renal replacement therapy or death) Hb recorded after PQ: Hb <7g/dL AND (dark, brown, or red urine or jaundice or shortness of breath or heart failure or blood transfusion or renal replacement therapy or death) Hb <7g/dL AND (dark urine or jaundice) AND (shortness of breath or heart failure or blood transfusion or renal replacement therapy or death) Hb <7g/dL AND (dark urine or jaundice) AND (shortness of breath or heart failure or blood transfusion or renal replacement therapy or death) Hb ≥7 g/dL AND (dark urine or jaundice) AND (shortness of breath or heart failure or blood transfusion or renal replacement therapy or death)
 Fall in Hb ≥5g/dL (Fall in Hb 3-4.99 g/dL or >25% fall) AND (dark, brown or red urine or jaundice or shortness of breath or heart failure or blood transfusion or renal replacement therapy or death) Hb recorded after PQ: Hb <7g/dL AND (dark, brown or red urine or jaundice) AND (shortness of breath or heart failur or blood transfusion or renal replacement therapy or death) ble o recorded: (dark urine or jaundice) AND (blood transfusion or renal replacement therapy or death) Hb recorded after PQ: Hb <7g/dL AND (dark, brown, or red urine or jaundice or shortness of breath or heart failure or blood transfusion or renal replacement therapy or death) Hb recorded after PQ: Hb <7g/dL AND (dark, brown, or red urine or jaundice or shortness of breath or heart failure or blood transfusion or renal replacement therapy or death)
 (Fall in Hb 3-4.99 g/dL or >25% fall) AND (dark, brown or red urine or jaundice or shortness of breath or heart failure or blood transfusion or renal replacement therapy or death) Hb recorded after PQ: Hb <7g/dL AND (dark, brown or red urine or jaundice) AND (shortness of breath or heart failur or blood transfusion or renal replacement therapy or death) ble o recorded: (dark urine or jaundice) AND (blood transfusion or renal replacement therapy or death) Hb recorded after PQ: Hb <7g/dL AND (dark, brown, or red urine or jaundice or shortness of breath or heart failure or blood transfusion or renal replacement therapy or death) Hb recorded after PQ: Hb <7g/dL AND (dark, brown, or red urine or jaundice or shortness of breath or heart failure or blood transfusion or renal replacement therapy or death)
 breath or heart failure or blood transfusion or renal replacement therapy or death) Hb recorded after PQ: Hb <7g/dL AND (dark, brown or red urine or jaundice) AND (shortness of breath or heart failur or blood transfusion or renal replacement therapy or death) ble o recorded: (dark urine or jaundice) AND (blood transfusion or renal replacement therapy or death) Hb recorded after PQ: Hb <7g/dL AND (dark, brown, or red urine or jaundice or shortness of breath or heart failure or blood transfusion or renal replacement therapy or death) Hb <7g/dL AND (dark, brown, or red urine or jaundice or shortness of breath or heart failure or blood transfusion or renal replacement therapy or death) Hb ≥7 g/dL AND (dark urine or jaundice) AND (shortness of breath or heart failure or blood
 Hb <7g/dL AND (dark, brown or red urine or jaundice) AND (shortness of breath or heart failur or blood transfusion or renal replacement therapy or death) ble o recorded: (dark urine or jaundice) AND (blood transfusion or renal replacement therapy or death) e Hb recorded after PQ: Hb <7g/dL AND (dark, brown, or red urine or jaundice or shortness of breath or heart failure or blood transfusion or renal replacement therapy or death) Hb <7g/dL AND (dark, brown, or red urine or jaundice or shortness of breath or heart failure or blood transfusion or renal replacement therapy or death) Hb ≥7 g/dL AND (dark urine or jaundice) AND (shortness of breath or heart failure or blood
or blood transfusion or renal replacement therapy or death) ble o recorded: (dark urine or jaundice) AND (blood transfusion or renal replacement therapy or death) Hb recorded after PQ: Hb <7g/dL AND (dark, brown, or red urine or jaundice or shortness of breath or heart failure or blood transfusion or renal replacement therapy or death) Hb ≥7 g/dL AND (dark urine or jaundice) AND (shortness of breath or heart failure or blood
 precorded: (dark urine or jaundice) AND (blood transfusion or renal replacement therapy or death) e Hb recorded after PQ: Hb <7g/dL AND (dark, brown, or red urine or jaundice or shortness of breath or heart failure or blood transfusion or renal replacement therapy or death) Hb ≥7 g/dL AND (dark urine or jaundice) AND (shortness of breath or heart failure or blood
(dark urine or jaundice) AND (blood transfusion or renal replacement therapy or death) Hb recorded after PQ: Hb <7g/dL AND (dark, brown, or red urine or jaundice or shortness of breath or heart failure or blood transfusion or renal replacement therapy or death) Hb \geq 7 g/dL AND (dark urine or jaundice) AND (shortness of breath or heart failure or blood
 Hb recorded after PQ: Hb <7g/dL AND (dark, brown, or red urine or jaundice or shortness of breath or heart failure or blood transfusion or renal replacement therapy or death) Hb ≥7 g/dL AND (dark urine or jaundice) AND (shortness of breath or heart failure or blood
Hb <7g/dL AND (dark, brown, or red urine or jaundice or shortness of breath or heart failure or blood transfusion or renal replacement therapy or death) Hb \geq 7 g/dL AND (dark urine or jaundice) AND (shortness of breath or heart failure or blood
blood transfusion or renal replacement therapy or death) Hb \geq 7 g/dL AND (dark urine or jaundice) AND (shortness of breath or heart failure or blood
Hb \geq 7 g/dL AND (dark urine or jaundice) AND (shortness of breath or heart failure or blood
transfusion or renal replacement therapy or death)
rtain
Not fulfilling probable or possible criteria but considered serious PQ-associated haemolysis by
authors
haemoglobin; PQ - primaquine
Hb = Hb reported before and after PQ administration
Hb = Hb reported only after PQ administration
ses required temporal association with PQ within the preceding 4 weeks.

163 First review - serious adverse events reported in clinical trials

164 Between January 1990 and August 2021, 249 published *P. vivax* clinical trials (428 treatment arms) were

identified, of which 138 (55.4%) fulfilled the inclusion criteria and were reviewed for SAEs (Figure 1). 70

- trials (124 treatment arms, 16,214 patients; 44 (62.9%) randomised studies) explicitly mentioned adverse
- 167 events and collectively included 9,824 patients treated with PQ. A further 6,390 patients were not treated
- 168 with PQ (table 1).

169 A total of 110 SAEs were reported, of which 68 (67.3%) were attributed by the authors to PQ treatment. 170 There were 37 episodes of acute haemolysis; 34 occurred in patients treated with PQ and 3 in patients treated without PQ. Three haemolytic SAEs occurred in patients with G6PD deficiency (<30%) who had 171 172 been treated with PQ in error. The reasons stated for classification as a haemolytic SAE included 16 patients who had a >2.5 g/dL drop 173 174 in Hb or >25% fall (in all cases PO was continued without interruption), 5 patients who had a >3 g/dL drop 175 in Hb or >30% fall (PQ was continued in 4 cases), 3 patients who had dark urine, and 6 patients who had a 176 fall in Hb to below 7g/dL (3 required blood transfusion and in two of the remaining cases PQ was 177 temporarily ceased and restarted). A further 6 patients, all in the same study, were hospitalised for 178 management, although their Hb nadir ranged from 8.5 to 13.2 g/dL, with a maximum absolute fall in Hb of 179 2 g/dL. One patient was reported as having acute haemolysis with jaundice (total bilirubin 105 µmol/L) but 180 no further details could be ascertained. Overall, 27.2% (10/37) of the reported haemolytic SAEs were 181 classified by us as 'severe' based on the need for hospitalisation, blood transfusion, renal replacement 182 therapy or death. 183 The risks of SAE and haemolysis in patients with unknown G6PD status or G6PD activity \geq 30% are

presented in Table 1. The overall incidence of PQ-associated haemolytic SAE (all PQ dosing regimens) was 188 [95% confidence interval (95%CI) 103-315] per 100,000 and the overall risk of severe PQ haemolysis was 107 [95%CI 46-212] per 100,000.

	Total	No PQ		Low Daily Dose PQ <0.375 mg/kg/day		Intermediate Daily Dose PQ 0.375 -<0.75 mg/kg/day		High Daily Dose PQ ≥0.75 mg/kg/day	
	n/N	n/N	Rate per 100,000 [95%CI]	<0.375 n/N	Rate per 100,000 [95%CI]	n/N	Rate per 100,000 [95%CI]	<u>≥0.75</u> n/N	Rate per 100,000 [95%CI]
Any SAE									
No Testing	24/5707	1/3599	28 [1-155]	9/1048	859 [393-1624]	14/1060	1321 [724- 2206]	-	-
Testing >30%	83/10,056	7/2604 ^b	269 [108-554]	12/2658 °	452 [234-787]	31/3466	894 [609- 1267]	33/1328	2485 [1717- 3472]
Any PQ-Related SAE									
No Testing	22/5707	1/3599	28 [1-154]	8/1048	763 [330-1499]	13/1060	1226 [655- 2088]	-	-
Testing >30%	50/10,056	3/2604 ^b	115 [24-336]	11/2658 °	414 [207-739]	16/3466	462 [264-749]	20/1328	1506 [922-2316]
Haemolytic SAE									
No Testing	17/5707	0/3599	0	5/1048	477 [155-1110]	12/1060	1132 [586- 1969]	-	-
Testing > 30%	17/10,056	3/2604 ^b	115 [24-336]	8/2658 °	301 [130-592]	1/3466	29 [1-161]	5/1328	376 [122-876]
Females >30%	9/2782	0/632	0	4/757 °	661 [215-1535]	0/876	0	5/517	967 [315-2242]
Severe Haemolytic SAE ^a									
No Testing	0/5707	0/3599	0	0/1048	0	0/1060	0	-	-
Testing >30%	8/10,056	0/2604 ^b	0	5/2658 ^{c, d}	188 [61-438]	0/3466	0	3/1328 e	226 [47-660]
Females >30%	7/2782	0/632	0	4/757 ^{c, d}	661 [215-1535]	0/876	0	3/517 ^e	580 [120-1696]

187 Table 1 Risks of serious adverse events reported in clinical trials

188

189 Numerators exclude patients with G6PD deficiency (≤30%) enrolled and treated in error. Denominators excluded 68 trials (16,584 patients

190 treated with PQ, and 8,587 without PQ) in which no SAEs were reported, and in which no mention was made of reporting of SAEs in methods or

191 *results. Raw data presented in Review1b and Review1c sheets in Data File.*

^{*a*} *Fulfilling criteria of haemolysis requiring hospitalisation, blood transfusion, renal replacement therapy or death*

193 ^b Excludes 187 patients tested at >70% activity.

194 *c Excludes 264 patients tested at >70% activity.*

^d All five cases (4 females) came from one study and were hospitalised with jaundice and dark urine but minor falls in haemoglobin (0.6-2.0g/dL)

196 ^{*e*} *Three heterozygous females, two requiring blood transfusion.*

199 Second Review - Reports of Severe Haemolysis

200 In the second review, a total of 8,487 articles were identified describing patients with vivax malaria 201 requiring admission to hospital. After removal of 1,167 duplicate publications, addition of a further 239 202 articles (identified from clinical trials and previous reviews) and exclusion of articles after screening of the 203 titles and abstracts, a total of 76 articles remained for full-text review (figure 1). 55 studies were 204 subsequently excluded because they did not report patients fulfilling the criteria for severe PO-associated 205 haemolysis. A total of 163 individuals with severe PQ-associated haemolysis were identified from 21 206 articles published between 1953 and 2020: 43 were from Asia (13 articles), 116 from South America (5 207 articles), 3 from North America (2 articles) and 1 from Oceania (1 article) (Figure 1). 17 patients (8 articles) 208 were reported in randomised controlled trials and 146 patients (13 articles) were reported in case reports.

A summary of the studies included in the analysis is provided in the Supplementary Data File.

The median age of individuals with severe PQ-associated haemolysis was 18 (IQR: 12 - 28; range 1 - 84)

211 years and 132 (80.9%) were males. Overall, 134 (82.2%) patients had *P. vivax* infection and 6 (3.7%) had

212 mixed *P. vivax* and *P. falciparum* infection. A further 23 individuals (14.1%) were negative when tested

for malaria, 19 of whom were presumed by the authors to have had previous *P. vivax* infection. Of the 140

individuals treated for acute malaria, 135 (96.4%) also received chloroquine, 4 (2.9%) dihydroartemisinin-

215 piperaquine and 1 (0.7%) amodiaquine.

The duration of the PQ regimen prescribed was reported in 156 cases. Eighteen (11.5%) were prescribed 14 days of treatment, one (0.6%) 8 days treatment, 121 (77.6%) 7 days treatment and 16 (10.3%) 5 days or less. Two (1.3%) patients were prescribed weekly PQ for eight weeks. The target daily PQ doses prescribed are provided in Table 2. The total dose prescribed was <2.5 mg/kg for 16 (10.3%) patients, 2.5-5 mg/kg for 132 (84.6%) patients and \geq 5 mg/kg for 8 (5.1%) patients.

G6PD status was recorded for 159 (97.5%) of the 163 patients, with a qualitative assay used in 145 (91.2%)

patients and a quantitative assay in 10(6.3%) patients. The assay method was not stated in 4(2.5%) cases.

223 Overall, 150 (94.3%) individuals were categorised as G6PD deficient and two (1.3%) had intermediate

224 G6PD deficiency. Seven (4.4%) patients were G6PD normal according to a qualitative G6PD test (assumed

to have \geq 30% activity), four of whom were female. The certainty of the diagnosis of severe PQ-associated haemolysis was categorised as probable in 48 (29.5%) cases, possible in 53 (32.5%) cases and uncertain in 62 (38.0%) cases. G6PD activity was documented in 94 of the patients with probable or possible severe haemolysis, of whom 96.8% (n=91) were G6PD deficient (<30% activity) and 3 were heterozygous females (64%, 94% and >30% enzyme activity respectively).

230

231 Clinical presentation and management of patients

All subsequent results are restricted to the 101 patients with probable or possible severe PQ-related

haemolysis, 95 of whom were G6PD deficient (<30%), (three patients were heterozygous females and three

234 patients did not have a reported G6PD status). The most common clinical presentations of haemolysis were

pallor (92.0%, 69/75), dark urine (85.1%, 63/74) and jaundice (90.2%, 83/92) (table 2).

Fourteen patients had a haemoglobin measurement before and after initiation of PQ. In these patients the

median fall in haemoglobin was 4.4 g/dL (IQR: 3.7 - 6.6; Range: 2.2 - 8.9). Of the patients in whom serum

bilirubin was measured, 88% (66/75) had raised total bilirubin concentration (median = 4 mg/dL,

interquartile range [IQR]: 2.1 - 5.5; range: 0.3 - 46.4). At the time that patients were hospitalised, 79.5%

240 (58/73) of those with acute malaria were aparasitaemic, however 55.3% (26/47) were febrile and 62.5%

241 (30/48) had a raised total white cell count.

Clinical manifestations of severe haemolysis		robable PQ- associated N=48		ssible PQ- ssociated N=53	Uncertain PQ- associated N=62	
	Ν	n (%)	Ν	n (%)	Ν	n (%)
Symptoms & signs						
Dark urine	36	29 (80.6)	38	34 (89.5)	39	38 (97.4)
Pallor	40	38 (95.0)	35	31 (88.6)	40	36 (90.0)
Dyspnoea	33	9 (27.3)	26	7 (26.9)	30	2 (6.7)
Dizziness	17	9 (52.9)	9	4 (44.4)	8	3 (37.5)
Fever	38	24 (63.2)	31	16 (51.6)	32	7 (21.9)
Severe fatigue	20	13 (65.0)	6	5 (83.3)	3	2 (66.7)
Heart failure	31	3 (9.7)	31	6 (19.4)	33	0 (0.0)
Chest pain	7	1 (14.3)	3	0 (0.0)	0	0 (0.0)
Jaundice	44	39 (88.6)	48	44 (91.7)	54	47 (87)
Low urine output	14	2 (14.3)	4	0 (0.0)	5	2 (40)
Laboratory findings						
Glucose 6-Phosphate dehydrogenase						
Normal	47	0 (0.0)	51	2 (3.9)	61	5 (8.2)
Intermediate	47	2 (4.4)	51	0 (0.0)	61	0 (0.0)
Deficient	47	45 (95.7)	51	49 (96.1)	61	56 (91.8)
Total bilirubin, >1 mg/dL	37	31 (83.8)	38	35 (92.1)	52	46 (88.5)
Indirect bilirubin, >0.8 mg/dL	36	30 (83.3)	36	33 (91.7)	43	37 (86.1)
Urine dipstick blood, positive	21	10 (47.6)	27	19 (60.4)	31	21 (67.7)
Urine dipstick urobilinogen, positive	20	3 (15)	25	14 (66)	30	12 (40)
White blood cell count, $>12,000/\mu L$	32	20 (62.5)	38	20 (52.6)	36	10 (27.8)
Target daily dose of PQ						
0.25 mg/kg/day	47	5 (10.6)	52	12 (23.1)	57	14 (24.6)
0.5 mg/kg/day	47	36 (76.6)	52	39 (75.0)	57	43 (75.4)
0.75 mg/kg/day	47	2 (4.3)	52	0 (0.0)	57	0 (0.0)
1.0 mg/kg/day	47	4 (8.5)	52	1 (1.9)	57	0 (0.0)
Management						
Blood transfusion	48	45 (93.8)	42	32 (76.2)	43	0 (0.0)
Renal replacement therapy	39	4 (10.3)	41	4 (9.8)	42	0 (0.0)
Hospitalised (no blood transfusion or renal replacement therapy)	3	3 (100)	19	19 (100)	62	62 (100)
Outcome						
Died	48	0 (0.0)	53	7 (13.2)	62	0 (0.0)

243 Table 2 Characteristics and clinical outcomes of individuals with severe PQ-associated haemolysis

245 N = number of patients for whom data were available. n = number of patients with manifestation present

246

247 Timing of severe PQ-associated haemolysis

248 Information on the timing of manifestations of severe PQ-associated haemolysis was available for 93 249 (92.1%) patients, with all patients presenting within the first 7 days of commencing PQ treatment. Overall, 89.2% (83/93) developed symptoms of haemolysis within 4 days of commencing PQ. The first symptoms 250 251 of haemolysis were mostly reported on day 2 or 3 (43.3%) after commencing PQ, whereas onset of severe 252 haemolysis occurred most frequently on day 3 or 4 (55.4%) (figure 2). At the onset of manifestations of 253 severe haemolysis, PQ had been taken for a median of 4 days (range 1-8) with a median total dose received of 2.0 mg/kg (IOR: 1.5-2.5, Range: 0.3-5.0) (figure S1 appendix pp7). In total, 82.8% (82/99) of the cases 254 255 of probable or possible PQ-associated severe haemolysis occurred following administration of a daily dose 256 $\geq 0.5 \text{ mg/kg}$ (figure 3).

257

258 Outcomes

259 83.5% (76/90) of patients with severe PQ-associated haemolysis required blood transfusion and 10.3% 260 (8/78) required renal replacement therapy. The absolute fall in Hb could not be calculated for any of the 261 patients requiring renal replacement therapy. Seven (6.9%) patients died. All but one of the deaths occurred 262 in males. Four deaths were reported in Sri Lankan children, all of whom received PQ for radical cure of P. 263 vivax. The cause of death was reported as cardiac failure from anaemia in three of these patients and 264 irreversible renal failure in one. Three deaths were reported in Brazilian patients, all males. Overall, 5 of 265 the 7 patients who died were reported to be G6PD deficient, with the G6PD status unknown in the remaining two cases. One of the patients who died received a blood transfusion, but information on blood transfusion 266 267 or renal replacement therapy was not documented for the remaining 6 patients. Of the patients who 268 survived, 72.7% (56/77) were discharged from hospital within one week of admission.

270 Table 3. Clinical manifestations and outcomes of patients with probable or possible severe PQ-

271 associated haemolysis

	Blood transfusion N=76		Renal replacement therapy N=8			Death N=7	All patients N=101	
	Ν	n (%)	Ν	n (%)	Ν	n (%)	Ν	n (%)
Clinical manifestations								
Dark urine	57	48 (84.2)	5	5 (100)	4	4 (100)	74	63 (85.1)
Pallor	60	56 (93.3)	8	7 (87.5)	2	2 (100)	75	69 (92.0)
Dyspnoea	47	8 (17.0)	7	2 (28.6)	3	3 (100)	59	16 (27.1)
Dizziness	22	11 (50.0)	4	1 (25.0)	0	0 (0.0)	26	13 (50.0)
Fever	58	37 (63.8)	7	4 (57.1)	1	1 (100)	69	40 (57.8)
Severe fatigue	21	15 (71.4)	0	0 (0.0)	0	0 (0.0)	26	18 (69.2)
Heart failure	51	7 (13.7)	6	6 (100)	0	0 (0.0)	62	9 (14.5)
Chest pain	8	1 (12.5)	8	0 (0.0)	0	0 (0.0)	10	1 (10.0)
Jaundice	67	59 (88.1)	7	7 (100)	6	6 (100)	92	83 (90.2)
Low urine output	14	2 (14.3)	3	2 (66.7)	0	0 (0.0)	18	2(11.1)
Laboratory findings								
Haemoglobin >3g/dl drop	11	9 (81.8)	0	0 (0.0)	0	0 (0.0)	14	12 (85.7)
Haemoglobin >25% fall	11	11 (100)	0	0 (0.0)	0	0 (0.0)	14	14 (100)
Total bilirubin > 1 mg/dL	59	51 (86.4)	7	5 (71.4)	1	1 (100)	75	66 (88.0)
Indirect bilirubin > 0.8 mg/dL	59	51 (86.4)	7	5 (71.4)	1	1 (100)	72	63 (87.5)
Urine dipstick blood, positive	31	17 (54.8)	6	3 (50.0)	5	5 (100)	48	29 (60.4)
Urobilinogen dipstick positive	30	5 (16.7)	5	1 (20.0)	3	3 (100)	45	17 (37.8)
White blood cell count > 12,000/µL	56	33 (58.9)	7	4 (57.1)	3	3 (100)	70	40 (57.1)

272

N = number of patients in whom data was available. n = number of patients with manifestation present

274 Patients could present with more than one outcome thus total number of patients does not equal

275 summation of those who received blood transfusion, renal replacement therapy, or who died.

277 Discussion

278 Radical cure of *P. vivax* malaria requires treatment of both blood and liver stages of the parasite to ensure 279 clinical recovery and reduce the risk of subsequent relapse. Without radical cure, relapses occur in up to 280 70% of patients, the risk and frequency of which vary with host immunity, background transmission intensity and geographical location.¹⁵ The antirelapse efficacy of PQ is related to the total dose of PQ 281 administered, whereas for the 7- and 14- day regimens the risk of haemolysis is related to the daily dose.^{16,17} 282 283 Since routine G6PD testing is often unavailable in malaria endemic countries, most national malaria control 284 programs currently recommend a total dose of 3.5 mg/kg administered over 14 days, allowing the daily dose to be reduced to 0.25 mg/kg to minimise haemolysis. 285

Adherence to standard 14-day PQ regimens is typically poor.¹⁸ Seven-day regimens of higher daily doses of PQ (0.5 mg/kg) are used routinely in several endemic countries including Brazil, Peru and China,¹⁰ providing a total dose of 3.5 mg/kg. Recent evidence suggests that 7 mg/kg may be required to reduce the risk of recurrent parasitaemia to less than 10% in areas of both high and low relapse periodicity.^{19,20} Giving 7mg/kg over 7- as opposed to 14-days (1 mg/kg/day) is equally efficacious but the increased daily dose is associated with greater risk of SAE.^{21,22}

292 A total of 37 haemolytic SAEs were reported in the clinical trials in our first review, 34 of which occurred 293 following PO administration. The criteria used to classify these adverse events as serious varied. 21 294 reported SAEs were based solely on a significant fall in haemoglobin (>2-3 g/dL) with all but one of these 295 patients continuing their course of PQ to completion. In total 10 of the patients with reported SAEs required 296 hospitalisation and blood transfusion for medical management. The overall risk of severe PQ haemolysis 297 was estimated to be 107 per 100,000 patients with normal G6PD activity (\geq 30% activity) treated with PQ. 298 The prospective clinical trials in our reviews generally applied more conservative criteria for classifying 299 adverse events as serious (presumably with the aim of ensuring patient safety in a controlled environment) 300 than the case reports and pharmacovigilance studies in our second review. The latter often had limited 301 clinical and laboratory information available prior to the onset of the events. Even when comprehensive data are available, the clinical and laboratory features that justify haemolysis being classified as serious or 302

303 life-threatening have yet to be defined. This results in a lack of consistent data for decision-makers to 304 balance the risks of PQ radical cure with the risks of multiple relapses of vivax malaria in different endemic 305 locations.¹ Quantifying these risks will require robust definitions of haemolysis that can accommodate 306 differential access to laboratory investigations. Standardised templates for reporting relevant clinical and 307 laboratory details of potential haemolytic events will facilitate this process greatly. An example of a form 308 for reporting the key data identified in our analysis is provided (appendix pp 8-12).

309 The second of our systematic reviews included all articles published since the introduction of PQ. The 310 largest case series were reported from South America, where the prevalence of G6PD deficiency is high and comparatively large daily doses (0.5 mg/kg) of PQ are recommended.^{8,23} Conversely none of the cases 311 in this review were reported from Africa, where G6PD deficiency is mostly attributable to the mild A-312 variant.⁵ Based on a priori criteria for certainty of association, 101 cases of severe haemolysis were 313 314 categorised as probably or possibly related to PQ, all but one of which occurred in patients with either 315 intermediate or severe G6PD deficiency. The first signs and symptoms of haemolysis occurred within four days of starting treatment in over 90% of cases, with hospitalisation occurring most frequently on day 4 316 317 after a median total dose of 2 mg/kg. All patients presented to hospital within the first week after starting 318 PQ. Most cases occurred in patients receiving $\geq 0.5 \text{ mg/kg/day}$. The signs and symptoms of severe PQ-319 associated haemolysis in our review concurred broadly with those found in G6PD deficient patients treated with the sulphur-based antimalarial drug dapsone.²⁴ 320

321 A total of 12 deaths probably or possibly related to PQ-associated haemolysis have been reported in the 322 scientific literature, of which seven followed PQ for radical cure of P. vivax and were included in our second review.⁴ Although other deaths have undoubtedly occurred and gone unreported, this outcome is rare, with 323 324 estimates varying from 1 in 625,000 to 1 in 110,000 patients treated with PQ.^{4,8} Of the seven patients in our analysis who died, five had recorded G6PD status and were deficient at the 30% threshold.^{8,25,26} Of the 101 325 326 patients with probable or possible severe haemolysis, 98 had G6PD status recorded and all but three of 327 these patients had G6PD deficiency with activity less than 30%. The remaining three patients were heterozygous females treated with high dose PQ (1mg/kg/day).²¹ Although there is an increased risk of 328

haemolysis in heterozygous females with intermediate deficiency (30-70%),²⁷ our findings suggest that for low (0.25 mg/kg) and intermediate (0.5mg/kg) daily doses, severe haemolysis can be minimised by a reliable qualitative test used to exclude exposure of individuals with less than 30% enzyme activity.

332 Widespread point-of-care testing for G6PD deficiency prior to PQ administration will facilitate exclusion 333 of patients at greatest risk of haemolysis and reduce adverse drug reactions. However, even in optimal 334 conditions, G6PD testing is not 100% reliable and due to logistical, financial and supply constraints, quality 335 tests may not always be available. In these cases the risks of PQ-associated haemolysis need to be balanced against the cumulative risks of recurrent episodes of parasitaemia and associated morbidity and 336 mortality.^{1,28} In this context it is critical to understand the clinical presentation and outcomes of severe PQ-337 associated haemolysis, so that patients with impending haemolysis can be identified and mitigating 338 339 strategies taken to avoid further deterioration.

340 PQ-associated haemolysis is most prominent during the first week of treatment, as circulating senescent erythrocytes with low G6PD activity and greatest vulnerability to oxidant stress are cleared.²⁷ With time, 341 342 increased production of relatively G6PD replete reticulocytes partially compensates for the increased red cell loss and increases the median tolerance of circulating erythrocytes to oxidative stress.²⁹ This 343 344 presumably explains the lack of new presentations with severe haemolysis beyond one week of starting PQ 345 treatment. Hospitalisation was delayed with respect to symptom onset by one to two days suggesting that there is an opportunity to prevent severe manifestations of haemolysis with early intervention. Based on 346 347 these observations, routine clinical review within 5 days of starting PQ would identify most patients at risk 348 of severe haemolysis and allow early cessation of PQ to prevent further clinical deterioration.

Strengths of this paper include the use of consistent and strict *a priori* definitions for severe haemolysis and categorisation of likelihood of a causal association with PQ. Individualised patient data were used and authors approached for additional unpublished information. Despite this, clinical information available for many patients was insufficient to enable a full assessment of likely causality. Our assessment of the frequency of severe PQ-associated haemolysis will have been subject to ascertainment bias as many cases will not have been formally reported in the medical literature. Conversely, despite our attempts to define a

causal association with drug administration, some haemolytic events may have been inadvertently attributed to PQ. A previous pooled analysis has shown that approximately 1 in 1,000 patients with *P. vivax* malaria treated without PQ had acute falls in haemoglobin >5 g/dL,¹⁵ remarkably similar to the risk of severe haemolysis we estimated in patients with >30% enzyme activity (107 per 100,000). In our series, four G6PD deficient patients developed severe haemolysis on the day of initial presentation within hours of receiving the first dose of PQ. It is likely that these cases were attributable to acute malaria rather than drug administration.

362 In conclusion, severe PQ-associated haemolysis with clinical decompensation requiring urgent medical 363 intervention is rare but when it does occur, the first signs tend to become apparent within 2 to 3 days of starting treatment. Routine clinical review within 5 days to screen for symptoms such as dark urine, 364 jaundice, pallor, severe fatigue and fever would facilitate early detection of the majority of cases of 365 366 impending severe haemolysis enabling remedial action to be taken to prevent adverse outcomes. Diverse 367 criteria have been used to categorise haematological SAEs and this limits comparisons of their frequency between different locations and dosing regimens. Standardised definitions would facilitate valid 368 369 pharmacovigilance in clinical trials and real-world settings. Whilst widely available point-of-care testing 370 for G6PD deficiency will be critical for reducing the risk of severe adverse drug reactions in vulnerable 371 patients, severe haemolysis may still occur due to parasite-induced haemolysis, idiosyncratic reactions and 372 diagnostic errors. Hence any public health intervention must include community engagement to ensure patients and healthcare providers are aware of the haemolytic risks of malaria and its treatment and the need 373 374 to represent for medical review in case of clinical deterioration.

375

376 Funding

377 The research was funded in whole, or in part, by the Bill & Melinda Gates Foundation [SEPRA-INV-

378 024389]. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any

379 Author Accepted Manuscript version arising from this submission. DY was funded by WHO-TDR

- 380 Clinical Research and Development Fellowship. RNP is funded by an Australian National Health and
- 381 Medical Research (NHMRC) Leadership Investigator Grant (2008501), RJC by an NHMRC Investigator
- 382 Grant (1194702), KT by a CSL Fellowship, M.L. and W.M. by Conselho Nacional de Desenvolvimento
- 383 Científico e Tecnológico (CNPq productivity scholarships) and JDBS by the Research Support
- 384 Foundation of the State of Amazonas. The funders of the study had no role in study design, data
- 385 collection, analysis, interpretation of data or writing of the report.

386 Acknowledgements

- 387 We thank the investigators of several reports for providing additional information on serious adverse
- 388 events, including André Daher and Kevin Baird.

389 Contributors

- 390 DY, EG, RC, RP and ND conceptualised the study. All authors were responsible for data collection and
- 391 curation. DY, RP, RC and ND analysed the data. All authors helped interpret the data. DY, RP and ND
- 392 wrote the original draft of the paper. All authors reviewed and edited the paper.

393 Conflict of Interest

394 All authors declare they have no conflicts of interest

395 **References**

- World Health Organisation. Guidelines for the treatment of malaria 3rd edition. Geneva: WHO,
 2015.
 Luzzatto L, Ally M, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. *Blood* 2020;
- **400 136**(11): 1225-40.
- 401 3. Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. *Malar J* 2014; **13**: 418.
- 402 4. Recht J, Ashley E, White NJ. Safety of 8-aminoquinoline antimalarial medicines. Geneve,
- 403 Switzerland: World Health Organisation, 2014.
- 404 5. Howes RE, Piel FB, Patil AP, et al. G6PD deficiency prevalence and estimates of affected
- populations in malaria endemic countries: a geostatistical model-based map. *PLoS medicine* 2012; 9(11):
 e1001339.
- 407 6. Clarke GM, Rockett K, Kivinen K, et al. Characterisation of the opposing effects of G6PD
 408 deficiency on cerebral malaria and severe malarial anaemia. *Elife* 2017; 6.
- 409 7. Plewes K, Kingston HWF, Ghose A, et al. Cell-free hemoglobin mediated oxidative stress is
- 410 associated with acute kidney injury and renal replacement therapy in severe falciparum malaria: an
- 411 observational study. *BMC Infect Dis* 2017; **17**(1): 313.
- 8. Brito-Sousa JD, Santos TC, Avalos S, et al. Clinical Spectrum of Primaquine-induced Hemolysis
- 413 in Glucose-6-Phosphate Dehydrogenase Deficiency: A 9-Year Hospitalization-based Study From the
- 414 Brazilian Amazon. *Clin Infect Dis* 2019; **69**(8): 1440-2.
- 415 9. Thriemer K, Ley B, Bobogare A, et al. Challenges for achieving safe and effective radical cure of
- 416 Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group. *Malar J* 2017; **16**(1):
- **417** 141.
- 418 10. Recht J, Ashley EA, White NJ. Use of primaquine and glucose-6-phosphate dehydrogenase
- 419 deficiency testing: Divergent policies and practices in malaria endemic countries. PLoS Negl Trop Dis
- 420 2018; **12**(4): e0006230.

421	11	Douglas NM, Lampah DA, Kenangalem E, et al. Major burden of severe anemia from non-
421	11.	Dougras NWI, Lamban DA, Kenangarenn E, et al. Wator burden of severe anenna from non-

- falciparum malaria species in southern papua: a hospital-based surveillance study. *PLoS medicine* 2013;
 10(12): e1001575.
- 424 12. Douglas NM, Pontororing GJ, Lampah DA, et al. Mortality attributable to Plasmodium vivax
- 425 malaria: a clinical audit from Papua, Indonesia. *BMC medicine* 2014; **12**: 217.
- 426 13. Commons RJ, Thriemer K, Humphreys G, et al. The Vivax Surveyor: Online mapping database
- 427 for Plasmodium vivax clinical trials. *Int J Parasitol Drugs Drug Resist* 2017; **7**(2): 181-90.
- 428 14. Office for Human Research Protections. Reviewing and reporting unanticipated problems
- 429 involving risks to subjects or others and adverse events: OHRP guidance (2007). January 15, 2007 2007.
- 430 https://www.hhs.gov/ohrp/regulations-and-policy/guidance/reviewing-unanticipated-problems/index.html
- 431 (accessed January 26 2023).
- 432 15. White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. *Malar J* 2011; 10:
 433 297.
- 434 16. Baird JK. 8-Aminoquinoline Therapy for Latent Malaria. *Clin Microbiol Rev* 2019; **32**(4).
- 435 17. Commons RJ, Simpson JA, Thriemer K, et al. The haematological consequences of Plasmodium

436 vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial

437 Resistance Network systematic review and individual patient data meta-analysis. *BMC medicine* 2019;

438 17(1): 151.

18. Douglas NM, Poespoprodjo JR, Patriani D, et al. Unsupervised primaquine for the treatment of

440 Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study. PLoS medicine

- 441 2017; **14**(8): e1002379.
- Chamma-Siqueira NN, Viana GMR, Macedo de Oliveira A. Higher-Dose Primaquine to Prevent
 Relapse of Plasmodium vivax Malaria. Reply. *N Engl J Med* 2022; **387**(3): 283.

444 20. Commons RJ, Rajasekhar M, Simpson JA, Price RN, WWARN Vivax Primaquine Efficacy

445 TaSSG. Effect of primaquine dose of the risk of recurrence in patients with uncomplicated Plasmodium

vivax: a systematic review and individual patient data meta-analysis. International Congress of P vivax
Research. Online; 2022.

Chu CS, Phyo AP, Turner C, et al. Chloroquine Versus Dihydroartemisinin-Piperaquine With
Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria. *Clin Infect Dis* 2019; **68**(8): 1311-9.

Taylor WRJ, Thriemer K, von Seidlein L, et al. Short-course primaquine for the radical cure of
Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. *Lancet*2019; **394**(10202): 929-38.

454 23. Ramos Junior WM, Sardinha JF, Costa MR, Santana MS, Alecrim MG, Lacerda MV. Clinical

455 aspects of hemolysis in patients with P. vivax malaria treated with primaquine, in the Brazilian Amazon.

456 *Braz J Infect Dis* 2010; **14**(4): 410-2.

457 24. Pamba A, Richardson ND, Carter N, et al. Clinical spectrum and severity of hemolytic anemia in

458 glucose 6-phosphate dehydrogenase-deficient children receiving dapsone. *Blood* 2012; **120**(20): 4123-33.

459 25. Abeyaratne KP, Halpe NL. Sensitivity to primaquine in Ceylonese children due to deficiency of
460 erythrocytic glucose-6-phosphate dehydrogenase. *Ceylon Med J* 1968; 13(3): 134-8.

461 26. Lacerda MV, Fragoso SC, Alecrim MG, et al. Postmortem characterization of patients with

462 clinical diagnosis of Plasmodium vivax malaria: to what extent does this parasite kill? *Clin Infect Dis*463 2012; 55(8): e67-74.

Chu CS, Bancone G, Nosten F, White NJ, Luzzatto L. Primaquine-induced haemolysis in females
heterozygous for G6PD deficiency. *Malar J* 2018; **17**(1): 101.

466 28. Thriemer K, Poespoprodjo JR, Kenangalem E, et al. The risk of adverse clinical outcomes

467 following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia.

468 *PLoS Negl Trop Dis* 2020; **14**(11): e0008838.

469 29. Dern RJ, Beutler E, Alving AS. The hemolytic effect of primaquine. II. The natural course of the

470 hemolytic anemia and the mechanism of its self-limited character. J Lab Clin Med 1954; 44(2): 171-6.

472 **Research in Context**

473 **Evidence before this study**

474 Primaquine has been used since the 1950s for preventing relapses of *Plasmodium vivax* malaria but has the 475 potential to cause severe haemolysis, particularly in patients with glucose-6-phosphate dehydrogenase 476 (G6PD) deficiency. We did two systematic reviews to examine the definitions, frequency, timing, clinical 477 nature, management and outcomes of primaguine-induced haemolysis. In the first of two reviews, we 478 examined all studies in the WorldWide Antimalarial Resistance Network (WWARN) "vivax surveyor" 479 repository (previously registered at PROSPERO) and extracted all clinical trials published between January 480 1, 1990 and August 23, 2021 in which patients with *Plasmodium vivax* malaria were treated with either 481 partial or fully supervised primaquine therapy commencing within 7 days of blood schizontocidal therapy 482 and lasting for at least 5 days' duration. Studies not reporting adverse events were excluded. In the second 483 review, we searched PubMed, Web of Science, Embase and the Cochrane Central Database without 484 language restrictions from January 1, 1940 to May 20, 2020 for studies reporting severe primaguine-485 associated haemolysis using the terms vivax and (hospital* or renal or dialysis or transfusion or severe or 486 serious or haemolysis or hemolysis or fatal or death or died or methemoglobin* or methaemoglobin* or 'cerebral complicat*' or convuls* or unconscious* or prostrat* or 'kidney injury' or 'renal failure' or 'renal 487 488 impairment' or hemoglobinuria or haemoglobinuria or 'circulatory collapse' or shock or jaundice or 489 hyperbilirubinemia or hyperbilirubinaemia or 'hepatic dysfunction' or 'liver dysfunction' or bleeding or 490 hemorrhage or haemorrhage or thrombocytopenia or thrombocytopaenia or 'disseminated intravascular 491 coagulation' or DIC or 'acute respiratory distress syndrome' or ARDS or 'pulmonary edema' or 'pulmonary 492 oedema' or 'metabolic acidosis' or hyperlactat* or 'severe anemia' or 'severe anaemia' or hypoglycemia or 493 hypoglycaemia or complicat*). We also searched the WWARN repository of *P. vivax* clinical trials as well 494 as conference proceedings and reference lists of identified articles. The first review yielded 70 trials (124 495 treatment arms, 9,824 patients treated with primaguine) and the second review yielded 21 studies reporting 496 individualised data on patients with potential primaguine-associated haemolysis. National and subnational

guidelines for primaquine radical cure of vivax malaria vary markedly in different locations because of
differences in the perceived risk of primaquine-associated haemolysis and adverse consequences of vivax
malaria relapses. Some countries and territories omit primaquine altogether. There is no standardised
definition of serious or life-threatening primaquine-associated haemolysis, making comparisons of the
frequency of this feared outcome across different endemic locations difficult.

502

503 Added value of this study

504 Our first review provides the first population-level estimate of the frequency of severe primaquine-505 associated haemolysis requiring hospitalisation or blood transfusion of 107 per 100,000 patients with 506 normal G6PD activity treated with primaguine for vivax malaria. It also highlights a wide spectrum of 507 definitions used to classify haemolytic events as serious, many of which did not have important attendant 508 clinical outcomes. Our second review provides an exhaustive summary of severe primaquine-associated 509 haemolytic events reported in the medical literature. In total there have been 163 cases requiring 510 hospitalisation for haemolysis after primaquine for vivax malaria and 7 deaths, 5 of which occurred in 511 patients with known G6PD deficiency. Our review demonstrates that the first symptoms or signs of 512 impending severe haemolysis typically occur on day two or three of treatment and that need for 513 hospitalisation is delayed by a further one to two days.

514


515 Implications of all the available evidence


516 Severe primaquine-associated haemolysis is very rare but can be fatal. Since need for hospitalisation is 517 typically delayed with respect to symptom onset, clinical review within 5 days of initiation of treatment 518 could facilitate detection of impending severe haemolysis and enable remedial action. Definitions of serious 519 primaquine-associated haemolysis need to be standardised so that rates of haemolysis can be compared

- 520 across different endemic locations. A practicable point-of-care test for G6PD deficiency would increase the
- 521 safety of primaquine use but would not negate the need for improved, standardised pharmacovigilance.


522

523 Figures






- 526 Figure 1. Data extraction process for A) Review of SAEs in clinical trials and B) Review of severe
- 527 PQ-associated haemolysis



529 Figure 2. Timing of the first symptoms of haemolysis (A) and onset of severe haemolysis (B) after

530 commencing PQ




Number of days of PQ before severe haemolysis

531

Figure 3. Timing of hospital admission with severe PQ-associated haemolysis according to the daily dose of PQ (A) and total PQ dose administered at that time (B).

534 Footnote: Size and label of each dot indicates the number of events. Data restricted to 101 probable and

535 possible cases of severe PQ-associated haemolysis



536

537 Figure 4. Outcomes following severe PQ-associated haemolysis

- 538 Data restricted to 101 probable and possible cases of severe PQ-associated haemolysis
- 539
- 540